中国医疗前沿
中國醫療前沿
중국의료전연
CHINA HEALTHCARE INNOVATION
2013年
2期
47
,共1页
非淋菌性尿道炎%克拉霉素%阿奇霉素
非淋菌性尿道炎%剋拉黴素%阿奇黴素
비림균성뇨도염%극랍매소%아기매소
Non-gonococcal urethritis%Clarithromycin%Azithromycin
目的探讨比较克拉霉素与阿奇霉素治疗非淋菌性尿道炎的疗效.方法将我院收治的非淋菌性尿道炎患者随机分成克拉霉素组与阿奇霉素组各80例,比较两组患者疗效差异、不良反应发生率及复发率.结果治疗1个疗程后,阿奇霉素组总有效率和显效率分别为92.50%和68.75%,显著高于克拉霉素组的72.50%和52.50%,P <0.05;两组患者不良反应主要表现为腹痛、恶心呕吐和头痛头晕,发生率无显著差异;1个月后随访发现阿奇霉素组的复发率显著低于克拉霉素组.结论阿奇霉素治疗非淋菌性尿道炎疗效优于克拉霉素,且复发率低,两种药品都有一定的轻度不良反应发生.
目的探討比較剋拉黴素與阿奇黴素治療非淋菌性尿道炎的療效.方法將我院收治的非淋菌性尿道炎患者隨機分成剋拉黴素組與阿奇黴素組各80例,比較兩組患者療效差異、不良反應髮生率及複髮率.結果治療1箇療程後,阿奇黴素組總有效率和顯效率分彆為92.50%和68.75%,顯著高于剋拉黴素組的72.50%和52.50%,P <0.05;兩組患者不良反應主要錶現為腹痛、噁心嘔吐和頭痛頭暈,髮生率無顯著差異;1箇月後隨訪髮現阿奇黴素組的複髮率顯著低于剋拉黴素組.結論阿奇黴素治療非淋菌性尿道炎療效優于剋拉黴素,且複髮率低,兩種藥品都有一定的輕度不良反應髮生.
목적탐토비교극랍매소여아기매소치료비림균성뇨도염적료효.방법장아원수치적비림균성뇨도염환자수궤분성극랍매소조여아기매소조각80례,비교량조환자료효차이、불량반응발생솔급복발솔.결과치료1개료정후,아기매소조총유효솔화현효솔분별위92.50%화68.75%,현저고우극랍매소조적72.50%화52.50%,P <0.05;량조환자불량반응주요표현위복통、악심구토화두통두훈,발생솔무현저차이;1개월후수방발현아기매소조적복발솔현저저우극랍매소조.결론아기매소치료비림균성뇨도염료효우우극랍매소,차복발솔저,량충약품도유일정적경도불량반응발생.
Objective To investigate the differences in efficacy of clarithromycin and azithromycin in the treatment of non-gonococcal urethritis. Methods The patients with non-gonococcal urethritis admitted to the Agency Kang were randomly divided into two groups, the clarithromycin group and the azithromycin group, and 80 cases in each group. The differences in efficacy, incidence of adverse reactions, and the relapse rate of the two groups were compared. Results After a course of treatment, the total efficiency and remarkable efficiency rate of the azithromycin group was 92.50% and 68.75%, significantly higher than the clarithromycin group of 72.50% and 52.50%, P <0.05. The adverse reactions mainly were abdominal pain, nausea, vomiting and headache, dizziness, and there was no significant difference in the incidence. 1 month follow-up found that the recurrence rate of the azithromycin group was significantly lower than the clarithromycin group. Conclusion The efficacy of Azithromycin in the treatment of non-gonococcal urethritis is superior to clarithromycin, and the recurrence rate is low, and both the two drugs have some mild adverse reactions.